JAK1 — Drug Target
All drugs that target JAK1 — marketed and clinical-stage. Includes 4 drug classes acting on this target.
Drug classes
Janus kinase inhibitor · JAK inhibitor · Janus Kinase Inhibitor [EPC] · JAK1 inhibitor
Marketed (7)
- Abrocitinib 100 mg · Pfizer · Janus kinase inhibitor · Immunology
- Abrocitinib Suspension F1 · Pfizer · JAK inhibitor · Immunology
- Abrocitinib 200 MG Oral Tablet · Pfizer · JAK inhibitor
Abrocitinib 200 MG Oral Tablet is a small molecule that targets the JAK1 protein. - Abrocitinib Suspension F6 · Pfizer · JAK inhibitor · Immunology
- Abrocitinib 200 mg · Pfizer · JAK inhibitor · Immunology
- Abrocitinib tablet · Pfizer · JAK inhibitor
- ABROCITINIB · Janus Kinase Inhibitor [EPC]
CIBINQO works by reversibly inhibiting JAK1, blocking ATP binding and showing selectivity over other JAKs.
Phase 3 pipeline (4)
- OPA-15406 · Otsuka Pharmaceutical Development & Commercialization, Inc. · JAK1 inhibitor · Dermatology / Immunology
OPA-15406 is a selective JAK1 inhibitor that reduces inflammatory signaling to treat immune-mediated skin diseases. - Upadacitinib (ABT-494) · AbbVie · JAK inhibitor · Immunology
Upadacitinib is a Janus kinase (JAK) inhibitor that blocks the activity of JAK enzymes, which play a key role in the inflammatory response. - CXL · Pfizer · Janus kinase inhibitor · Rheumatology
CXL is a small molecule that inhibits the activity of a specific enzyme. - DR-102 · Teva Branded Pharmaceutical Products R&D, Inc. · Janus kinase inhibitor · Rheumatology
DR-102 is a small molecule that inhibits the activity of a specific enzyme.
Phase 2 pipeline (2)
- ARQ-151 cream 0.05% · Arcutis Biotherapeutics, Inc. · JAK1 inhibitor · Dermatology
ARQ-151 is a selective Janus kinase 1 (JAK1) inhibitor that modulates cytokine signaling involved in inflammatory responses. - ABT-494 · AbbVie · JAK1 inhibitor · Immunology
ABT-494 is a JAK1 inhibitor that selectively blocks Janus kinase 1 signaling to reduce inflammatory cytokine production and immune cell activation.